Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock
Your view on LXEO
Overview
What the company does, where it operates, and who runs it.
About Lexeo Therapeutics, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- R. Nolan Townsend
- Headquarters
- 345 Park Avenue South, New York City, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- R. Nolan Townsend
- Headquarters
- 345 Park Avenue South, New York City, US
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.
The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.
It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Lexeo Therapeutics, Inc. Common Stock, and the rating behind it. LXEO last traded at $4.25; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lexeo Therapeutics, Inc. Common Stock. Starting points for Lexeo Therapeutics, Inc. Common Stock: EPS -$1.02, beta 1.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lexeo Therapeutics, Inc. Common Stock. Lexeo Therapeutics, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lexeo Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Lexeo Therapeutics, Inc. Common Stock stands at -$1.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lexeo Therapeutics, Inc. Common Stock. Lexeo Therapeutics, Inc. Common Stock has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lexeo Therapeutics, Inc. Common Stock valued side by side against its closest peers. Lexeo Therapeutics, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Lexeo Therapeutics, Inc. Common Stock, and how their positions are changing. At a $333.7M market value, institutional positions materially move Lexeo Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Lexeo Therapeutics, Inc. Common Stock executives and directors. Shares of Lexeo Therapeutics, Inc. Common Stock have traded between $1.45 and $10.38 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Lexeo Therapeutics, Inc. Common Stock. Lexeo Therapeutics, Inc. Common Stock is a $333.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Lexeo Therapeutics, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lexeo Therapeutics, Inc. Common Stock. Coverage tracks Lexeo Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.